Scabies Clinical Trial - Ivermectin/ Permethrin for Scabies

Status Completed

Clinical Trial Summary

Scabies is a skin disease characterized by intense itching that worsens at night. It is very contagious, still has a high occurrence rate, and impacts patient quality of life. The use of scabicide followed by a clean and healthy lifestyle is the principle of scabies therapy. The primary treatment option for scabies is permethrin 5% cream. Ivermectin is an alternate treatment for scabies.

Clinical Trial Description

Permethrin acts by disrupting the sodium channel current, resulting in delayed repolarization, paralysis, and death of the parasite. Sodium channels are ubiquitous and therefore permethrin acts at all stages of the life cycle of the parasite. Permethrin 5% cream is applied overnight once a week for two weeks to the entire body. This drug has a number of negative side effects, such as being expensive, uncomfortable, less applicable, and in some cases resistant to permethrin. Ivermectin is an alternate treatment for scabies and should be administered twice, one week apart. Ivermectin acts by binding selectively and with high affinity to glutamate-gated chloride ion channels, which are present in invertebrate nerve and muscle cells, resulting in paralysis and death of the parasite. Two doses of ivermectin one week apart are recommended for scabies treatment. Due to its specific site of action, ivermectin may not be effective against the younger stages of the parasite inside the egg because the nervous system has not yet developed. This drug is safe, more affordable, more practical to use, and has minimal side effects. The disadvantage of ivermectin is it does not kill all the stages of S. scabiei, necessitating multiple doses. According to several earlier research, topical permethrin is just as effective as oral ivermectin at one or two doses. There hasn't been any research on how well three doses of oral ivermectin treat scabies. As a result of no data, our trial is looking forward to answering the comparison of the effectiveness between three dosages of oral ivermectin, two dosages of oral ivermectin, and two applications of topical permethrin in scabies patients. ;

Study Design

Related Conditions & MeSH terms

Scabies

Clinical Trial Details

NCT number	NCT05819983
Study type	Interventional
Source	Universitas Padjadjaran
Contact
Status	Completed
Phase	Phase 4
Start date	January 25, 2023
Completion date	March 6, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02572986` - A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies	Phase 3
Completed	`NCT00884728` - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory	N/A
Completed	`NCT05025696` - Efficacy and Side Effects of Blacksoap® as Adjuvant Therapy of Scabies	N/A
Completed	`NCT04205669` - Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon	Phase 4
Completed	`NCT02254564` - PCR (Polymerase Chain Reaction) Assay for Diagnosis of Sarcoptes Scabiei
Completed	`NCT03676140` - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )	Phase 3
Recruiting	`NCT05875441` - Efficacy and Safety Study of Moxidectin in Adults With Scabies	Phase 2
Completed	`NCT02978508` - Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.	Phase 3
Recruiting	`NCT04332068` - Ivermectin Safety in Small Children	Phase 2
Recruiting	`NCT04844905` - Adjunctive Ivermectin Mass Drug Administration for Malaria Control	Phase 3
Not yet recruiting	`NCT06380452` - Therapy for Scabies With Two Differently Concentrated Permethrin Creams	Phase 3
Completed	`NCT00604084` - Veron Scabies Education and Eradication Program	N/A
Completed	`NCT02485717` - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies	Phase 3
Completed	`NCT02485704` - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies	Phase 3
Recruiting	`NCT05310734` - PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies	Phase 4
Recruiting	`NCT04931680` - Risk Factors for Treatment Failure of Scabies in Autochthonous Populations of French Guiana (GUYAGALE)
Completed	`NCT05862701` - Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies	Phase 1
Not yet recruiting	`NCT05500326` - Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)	Phase 2
Recruiting	`NCT04814511` - Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)	Phase 3
Completed	`NCT05362513` - Comparative Study Between Topical Permethrin 5% and Oral Ivermectin for the Treatment of Scabies	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.